WO2007107384A3 - Inhibitoren der löslichen adenylatzyklase - Google Patents

Inhibitoren der löslichen adenylatzyklase Download PDF

Info

Publication number
WO2007107384A3
WO2007107384A3 PCT/EP2007/002706 EP2007002706W WO2007107384A3 WO 2007107384 A3 WO2007107384 A3 WO 2007107384A3 EP 2007002706 W EP2007002706 W EP 2007002706W WO 2007107384 A3 WO2007107384 A3 WO 2007107384A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenylate cyclase
cyclase inhibitors
soluble adenylate
soluble
inhibitors
Prior art date
Application number
PCT/EP2007/002706
Other languages
English (en)
French (fr)
Other versions
WO2007107384A2 (de
Inventor
Bernd Buchmann
Dirk Kosemund
Bernd Menzenbach
Martin Fritsch
Original Assignee
Bayer Schering Pharma Ag
Bernd Buchmann
Dirk Kosemund
Bernd Menzenbach
Martin Fritsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Bernd Buchmann, Dirk Kosemund, Bernd Menzenbach, Martin Fritsch filed Critical Bayer Schering Pharma Ag
Priority to EP07723652A priority Critical patent/EP2001843A2/de
Priority to JP2009500786A priority patent/JP2009530339A/ja
Priority to CA002646594A priority patent/CA2646594A1/en
Publication of WO2007107384A2 publication Critical patent/WO2007107384A2/de
Publication of WO2007107384A3 publication Critical patent/WO2007107384A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Zusammenfassung Die Erfindung betrifft Verbindungen der allgemeinen Formel (I) sowie deren Herstellung und Verwendung als Medikament.
PCT/EP2007/002706 2006-03-23 2007-03-22 Inhibitoren der löslichen adenylatzyklase WO2007107384A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07723652A EP2001843A2 (de) 2006-03-23 2007-03-22 Inhibitoren der löslichen adenylatzyklase
JP2009500786A JP2009530339A (ja) 2006-03-23 2007-03-22 可溶性アデニル酸シクラーゼインヒビター
CA002646594A CA2646594A1 (en) 2006-03-23 2007-03-22 Soluble adenylate cyclase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006014319.1 2006-03-23
DE102006014319A DE102006014319B4 (de) 2006-03-23 2006-03-23 Inhibitoren der löslichen Adenylatzyklase

Publications (2)

Publication Number Publication Date
WO2007107384A2 WO2007107384A2 (de) 2007-09-27
WO2007107384A3 true WO2007107384A3 (de) 2007-11-15

Family

ID=38438471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002706 WO2007107384A2 (de) 2006-03-23 2007-03-22 Inhibitoren der löslichen adenylatzyklase

Country Status (13)

Country Link
US (1) US20070259872A1 (de)
EP (1) EP2001843A2 (de)
JP (1) JP2009530339A (de)
KR (1) KR20090008261A (de)
CN (1) CN101448787A (de)
AR (1) AR060074A1 (de)
CA (1) CA2646594A1 (de)
DE (1) DE102006014319B4 (de)
DO (1) DOP2007000060A (de)
PE (1) PE20080173A1 (de)
TW (1) TW200815348A (de)
UY (1) UY30237A1 (de)
WO (1) WO2007107384A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2036906A1 (de) * 2007-09-05 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Azaindole als Inhibitoren der löslichen Adenylatzyklase
CN108096244B (zh) * 2018-01-25 2020-11-24 昆明医科大学 1-氢-2-吲哚酮-3-苄基/取代苄基-3-甲酸酯类化合物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070419A1 (en) * 2004-01-21 2005-08-04 Cornell Research Foundation, Inc. Chemical inhibitors of soluble adenylyl cyclase (sac)
WO2006032541A1 (de) * 2004-09-24 2006-03-30 Bayer Schering Pharma Aktiengesellschaft Indol derivative als inhibitoren der löslichen adenylatzyklase
WO2006131398A2 (en) * 2005-06-08 2006-12-14 Bayer Schering Pharma Aktiengesellschaft Inhibitors of soluble adenylate cyclase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544768B1 (en) * 1999-05-11 2003-04-08 Cornell Research Foundation, Inc. Mammalian soluble adenylyl cyclase
AU4018101A (en) * 1999-09-21 2001-04-24 Board Of Trustees Of The Leland Stanford Junior University Polynucleotides encoding human soluble adenylyl cyclase, polypeptides encoded thereby, and methods of use thereof
US20020064849A1 (en) * 2000-09-05 2002-05-30 Herr John C. Human soluble testicular adenylyl cyclase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070419A1 (en) * 2004-01-21 2005-08-04 Cornell Research Foundation, Inc. Chemical inhibitors of soluble adenylyl cyclase (sac)
WO2006032541A1 (de) * 2004-09-24 2006-03-30 Bayer Schering Pharma Aktiengesellschaft Indol derivative als inhibitoren der löslichen adenylatzyklase
WO2006131398A2 (en) * 2005-06-08 2006-12-14 Bayer Schering Pharma Aktiengesellschaft Inhibitors of soluble adenylate cyclase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SINCLAIR, M. L. ET AL.: "SPECIFIC EXPRESSION OF SOLUBLE ADENYLYL CYCLASE IN MALE GERM CELLS", MOLECULAR REPRODUCTION AND DEVELOPMENT, LISSS, NEW YORK, NY, US, vol. 56, no. 1, May 2000 (2000-05-01), pages 6 - 11, XP009040771, ISSN: 1040-452X *

Also Published As

Publication number Publication date
CN101448787A (zh) 2009-06-03
AR060074A1 (es) 2008-05-21
JP2009530339A (ja) 2009-08-27
DE102006014319B4 (de) 2009-01-08
TW200815348A (en) 2008-04-01
PE20080173A1 (es) 2008-04-30
KR20090008261A (ko) 2009-01-21
CA2646594A1 (en) 2007-09-27
US20070259872A1 (en) 2007-11-08
UY30237A1 (es) 2007-10-31
WO2007107384A2 (de) 2007-09-27
DE102006014319A1 (de) 2007-09-27
DOP2007000060A (es) 2007-10-15
EP2001843A2 (de) 2008-12-17

Similar Documents

Publication Publication Date Title
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
WO2009156462A3 (en) Organic compounds
WO2007093627A3 (de) Biozide zusammensetzung
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2007030361A3 (en) Benzimidazole thiophene compounds as plk inhibitors
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2009013545A3 (en) Chemical compounds
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2008046919A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
TW200615260A (en) Inhibitors of soluble adenylate cyclase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018643.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723652

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007723652

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2646594

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7885/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009500786

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020087025816

Country of ref document: KR